Ferrer and Medivir enter agreement for commercializing a new treatment for agitation associated with schizophrenia and bipolar disease in the Nordics

Medivir AB (Nasdaq OMX: MVIR) and Ferrer today announced that they have entered
a license and distribution agreement for the commercialization of ADASUVE®
(Staccato® Loxapine) in the Nordic region. In Europe, ADASUVE is approved for
the treatment of mild to moderate agitation of patients with schizophrenia or
bipolar disease.
Under the terms of the agreement, Ferrer grants to Medivir the exclusive rights
to promote, market, sell and distribute ADASUVE in the Nordic region – including
Denmark, Finland, Norway, Iceland and Sweden. ADASUVE is a hand-held inhaler
designed to deliver the drug to the deep lung, providing rapid systemic delivery
in a simple, non-invasive manner. Medivir thus becomes the exclusive supplier of
this new treatment therapy for the treatment of mild to moderate agitation of
patients with schizophrenia or bipolar disease. In return, Ferrer will receive
an up-front payment upon signature, and milestone payments conditional upon
cumulative sales performance.

“This licensing agreement is in line with our strategy to add new products to
our Nordic portfolio. ADASUVE is the first addition to the portfolio, which now
consists of 16 prescription pharmaceuticals” said Mr Maris Hartmanis, Medivir’s
CEO. He added, “ADASUVE is a very interesting product based on a novel
administration technology addressing an unmet medical need, which expands our
present offering to psychiatrists, Lithionit. We are excited about having
secured the commercial rights to ADASUVE for the Nordic region and the
partnership with Ferrer”.

“We belive that ADASUVE will be a breakthrough in the treatment of agitation and
is going to change the way in which the condition is viewed by both healthcare
professionals and patients”, said Mr. Antoni Villaró, Chief Operating Officer of
Ferrer. He added, “We are excited to be introducing ADASUVE to the European
psychiatric and hospital treatment community as ADASUVE is now available in
Germany, and thank to this agreement soon in the Nordic countries.”

“We take pride in developing a strong network of partners that, along with our
commercial resources, contribute to bring to the market innovative products
aimed at underserved conditions”, said Mr. Pedro de Antonio, Ferrer’s
International Director for Europe, Asia, Middle East and Africa.

For more information please contact:

Rein Piir, Medivir AB, Mobile: +46 (0)708 537 292

Nick Russell, Ferrer Communication: +34 93 6000 3860, nrussell@ferrergrupo.com

For partnering information:

Ana Aliaga, FerrerBusiness Development: +34 93 600 3867, aaliaga@ferrergrupo.com

About agitation
Agitation is a severe, disruptive, and morbid complication suffered by patients
with schizophrenia and bipolar disorders.

Patients who experience agitation describe feeling an inner distress that
progresses to an outwardly apparent dysfunctional state manifested by verbal
abuse, hostility, difficulty controlling impulses, uncooperative behavior and
increased potential for violence. While the time after which agitation requires
treatment can be variable (minutes, hours or days), once the patient escalates
to this point, urgent treatment is always required.

Currently, the standard of care in the treatment of acute agitation is
pharmacological tranquilization with antipsychotics, sometimes combined with
benzodiazepines.

ADASUVE, an inhaled formulation of the antipsychotic drug loxapine, begins to
control patients’ agitation in less than 10 minutes, intercepting the onset of
agitation in a noninvasive manner.

About ADASUVE (Staccato Loxapine)
ADASUVE combines the proprietary Staccato system with loxapine, an antipsychotic
medicinal product. The Staccato system is a hand-held inhaler that delivers a
drug aerosol to the deep lung resulting in intravenous-like pharmacokinetics and
rapid systemic effects.

ADASUVE has been approved for marketing in the EU by the European Commission.

For more information about ADASUVE, including the Summary of Product
Characteristics and Patient Information Leaflet approved in the EU please visit:
http://www.adasuve.com/index-eu.php

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor in late phase III clinical development
for hepatitis C that is being developed in collaboration with Janssen R&D
Ireland.

Medivir has also a broad product portfolio with prescription pharmaceuticals in
the Nordics.

For more information, visit www.medivir.com

About Ferrer
Ferrer is a privately-held European R&D-based pharmaceutical company
headquartered in Barcelona. It is active in the pharmaceutical, health, fine
chemicals and food sectors in Europe, Latin America, Africa, the Middle East,
Asia and the United States. In total, Ferrer's human healthcare products are
commercialized in more than 90 countries, through 23 international affiliates
(including joint ventures) and 70 partners and distributors.

Ferrer carries out activities throughout the full pharmaceutical value chain,
from R&D to international marketing, including fine chemical development and the
manufacturing of both raw materials and finished pharmaceuticals. Its research
centers in Spain and Germany, and manufacturing sites in Europe and Latin
America cover the pharmaceutical, diagnostics, vaccine, fine chemical, food and
feed sectors.

Ferrer holds the commercial rights for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries. ADASUVE® and Staccato® are
registered trademarks of Alexza Pharmaceuticals, Inc.

For more information, visit www.ferrergrupo.com